For HCPs - Regeneron

Caring for patients with eosinophilic gastritis with or without eosinophilic duodenitis?

Talk to your patients about Engage

With limited treatment options and cases on the rise for eosinophilic gastritis (EoG) with or without eosinophilic duodenitis (EoD), the Engage clinical research study is currently underway to investigate potential treatments. Consider Engage as an opportunity to see if an investigational product may be able to help your patients with EoG.

Engage is a phase 2/3 clinical study for adults and adolescents with EoG. The study consists of a screening period (up to 6 weeks), a 24-week placebo controlled, double-blind treatment period (Part A and Part B), a 28-week extended active treatment period (Part C), and a 12-week follow-up period.

This study aims to evaluate the safety and efficacy of an investigational drug. The drug is called “investigational,” as it has not yet been approved to treat EoG.

The study drug is administered as a subcutaneous injection. Participants will be trained on how to administer this injection themselves.

The study drug, assessments, and procedures will be provided at no cost to patients.

How can you help?

Engage is enrolling adults and adolescents globally. The success of Engage depends on physicians to refer potential study participants. Your patients may be eligible if they:

Are ≥ 12 years old*

Were diagnosed with EoG by endoscopic biopsy

Have had at least 2 EoG episodes every week in the 8 weeks before joining the study (stomach pain, stomach cramping, nausea, bloating, early satiety, loss of appetite, vomiting, diarrhea)

Please note: Other protocol-defined inclusion/exclusion criteria apply.

The study team will check your patient’s full medical history to see if they meet all inclusion criteria. Diversity in clinical studies is critical to developing better treatments – help ensure that your patients are represented.

If you have potentially eligible and interested patients, empower them with options and discuss the Engage clinical study. You may also contact the nearest study site to refer them.

*Age requirements may vary at different participating sites. For more information on site-specific age requirements to participate, please use the site finder tool on our website to learn more about the sites closest to you or your patients.

Find your nearest study site

Find a study site near you!

Your patient’s health and safety are our top priorities. We hope you value the impact of this research and will consider referring potential candidates. With your support, we hope to advance treatments for patients with EoG.